Adaptive Biotechnologies Corporation (ADPT) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	308.1M	277.0M	179.0M	170.3M	185.3M
Cost of Revenue	75.7M	71.4M	72.1M	75.6M	57.9M
Gross Profit	232.4M	205.6M	106.9M	94.7M	127.4M
Operating Expenses
R&D Expense	88.2M	93.8M	103.0M	122.1M	141.8M
SG&A Expense	180.4M	167.3M	157.6M	172.5M	184.1M
General & Admin Expense	79.7M	72.7M	72.8M	83.9M	88.5M
Selling & Marketing Expense	100.7M	94.6M	84.8M	88.6M	95.6M
Other Expenses	1.3M	1.7M	8.9M	27.1M	1.7M
Total Operating Expenses	269.9M	262.7M	269.4M	321.8M	327.6M
Cost and Expenses	345.5M	334.1M	341.5M	397.3M	385.5M
Operating Income (EBIT)	(37.5M)	(57.1M)	(162.5M)	(227.0M)	(200.2M)
Non-Operating
Interest Income	8.7M	9.4M	14.5M	15.5M	4.1M
Interest Expense	11.5M	11.8M	11.6M	13.8M	4.2M
Net Interest Income	(2.8M)	(2.3M)	3.0M	1.7M	(182.0K)
Other Non-Op Income/Expense	(26.5M)	(2.3M)	3.0M	1.7M	(182.0K)
Non-Operating Income (excl Interest)	(5.4M)	(9.4M)	(14.5M)	(15.5M)	(4.1M)
EBT (Pre-Tax Income)	(64.0M)	(59.5M)	(159.6M)	(225.3M)	(200.4M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(63.9M)	(59.5M)	(159.5M)	(225.3M)	(200.2M)
Earnings from Cont. Ops	(64.0M)	(59.5M)	(159.6M)	(225.3M)	(200.4M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(63.9M)	(59.5M)	(159.5M)	(225.3M)	(200.2M)
Per Share
Basic EPS	($0.41)	($0.39)	($1.08)	($1.56)	($1.00)
Diluted EPS	($0.41)	($0.39)	($1.08)	($1.56)	($1.00)
Revenue Per Share	$1.95	$1.83	$1.22	$1.18	$1.30
Shares
Basic Shares Outstanding	157.7M	151.7M	147.1M	144.4M	142.5M
Diluted Shares Outstanding	157.7M	151.7M	147.1M	144.4M	142.5M
Profitability Metrics
EBITDA	(16.0M)	(29.8M)	(128.8M)	(189.3M)	(175.2M)
D&A	16.1M	17.8M	19.3M	22.2M	20.9M
EBIT	(32.1M)	(47.7M)	(148.0M)	(211.5M)	(196.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026